Dengue fever secondary prevention

Jump to navigation Jump to search

Dengue Fever Microchapters

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Dengue fever from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Dengue fever secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Dengue fever secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Dengue fever secondary prevention

CDC on Dengue fever secondary prevention

Dengue fever secondary prevention in the news

Blogs on Dengue fever secondary prevention

Directions to Hospitals Treating Dengue fever

Risk calculators and risk factors for Dengue fever secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Although there is no commercially available vaccine for Dengue fever, it is notable that infection with one serotype is thought to produce lifelong immunity to that type, but only short term protection against the other three. Unfortunately, the risk of severe disease from secondary infection actually increases if someone previously exposed to serotype DENV-1 contracts serotype DENV-2 or DENV-3, or if someone previously exposed to DENV-3 acquires DENV-2.[1]

References

  1. Guzmán MG, Alvarez M, Rodríguez R, Rosario D, Vázquez S, Vald s L; et al. (1999). "Fatal dengue hemorrhagic fever in Cuba, 1997". Int J Infect Dis. 3 (3): 130–5. PMID 10460923.